Articles related to PRODUCT RECALL

Takeda’s decision to withdraw Exkivity from the US market raises questions about treatment alternatives for NSCLC patients with specific EGFR mutations; stay updated on this evolving situation.

Unprecedented eye drop recalls have led to significant health risks, including four fatalities. Learn more to ensure that you guide your patients towards safer, FDA-approved alternatives.

Marlex Pharmaceuticals has initiated a critical recall of specific lots of Digoxin Tablets due to a labeling error. Physicians are urged to exercise extreme caution and verify their inventory to prevent adverse patient outcomes.

Cipla’s recall of six batches of Albuterol Sulfate Inhalation Aerosol due to a container defect necessitates immediate attention for patient safety. Replacement inhalers must be obtained by consumers from these specific batches to prevent any potential adverse effects.

The business launched a precautionary global recall of desmopressin formulations used to treat mild-to-moderate hemophilia A and von Willebrand disease after higher-than-specified amounts of desmopressin were discovered in various formulations. Stimate, a nasal spray containing a synthetic form of desmopressin acetate used to control bleeding in hemophilia patients, is among the recalled products, as is Octostim Nasal Spray 1.5 mg/ml, DDAVP 10 micrograms (mcg)/0.1 ml, Minirin Nasal Spray 0.1 mg/ml, and Generic Desmopressin Acetate Nasal Spray 10 mcg/0.1 ml. Products containing higher-than-specified amounts of desmopressin were recalled due to concerns that increased desmopressin exposure can result in water retention, low blood pressure, and low blood salt levels in mild cases, as well as seizure, coma, and death.

The oral solution revealed 95% of the labeled amount of levothyroxine sodium (T4) for the affected lots. This recall does not apply to Tirosint capsules.